Kerecis introduces a new innovation to simplify surgical and trauma wound care with the launch of SurgiClose® Silicone, a product combining fish-skin grafts with silicone backing to improve treatment efficiency.
Kerecis, a leader in sustainable fish-skin technology for cellular therapy, has unveiled its latest product, SurgiClose® Silicone. This new addition to the SurgiClose® product family offers a groundbreaking solution for the treatment of surgical and trauma wounds by integrating a fish-skin graft with a silicone backing. Available in two variations—SurgiClose® Silicone Adhesive, featuring overlapping borders, and SurgiClose® Silicone Standard, with non-overlapping borders—the product aims to streamline wound care procedures.
Fertram Sigurjonsson, Founder and CEO of Kerecis, emphasized the significance of the new product, noting that traditional wound management often requires multiple supporting products such as sutures, staples, and dressing layers. “The new SurgiClose® Silicone combines fish-skin with a silicone contact layer, eliminating the need for one of these supporting products. This simplification not only enhances the workflow in surgical settings but also makes the process more cost-effective,” Sigurjonsson explained.
SurgiClose® Silicone is designed for use in the operating room to manage trauma and surgical wounds. By incorporating a silicone backing, the product enhances the attachment and protection of the fish-skin graft, which supports the body’s natural healing processes.
About Kerecis
Kerecis, founded by Fertram Sigurjonsson, specializes in developing fish-skin and fatty acid products for tissue regeneration, cellular therapy, and wound healing. The company’s patented fish-skin material, which closely mimics human tissue, is harvested from cold-water fish, ensuring a safe, disease-free graft that promotes accelerated healing. Clinical studies have shown Kerecis products outperform traditional wound-care solutions in healing speed.
Kerecis is a pioneer in the use of intact fish-skin for medical applications and remains the only global manufacturer of medical devices containing this material. The company’s growth has positioned it as the fastest-growing player in the U.S. biologics skin market. Kerecis’s product portfolio includes SurgiBind®/SurgiClose®, GraftGuide®, MariGen®, and Shield™, catering to a range of medical needs.
In line with its commitment to sustainability, Kerecis uses sustainably sourced Icelandic fish and renewable energy in its production processes. The company is part of Coloplast, a global leader in intimate healthcare products.
Related topic:
Skinsation LA Expands Injectable Services for Enhanced Beauty
Quttainah Specialized Hospital Hosts Major Plastic Surgery Symposium
Sofie Pavitt Brings Acne Skincare Line to Sephora